Hepatocellular carcinoma cell proliferation (HCC cell proliferation)

Hepatocellular carcinoma (HCC) cell proliferation refers to the rapid and uncontrolled division of malignant hepatocytes, which is a defining hallmark of primary liver cancer. This entry does not represent a single molecular target like a receptor or enzyme, but rather a complex biological phenotype driven by the dysregulation of multiple intracellular signaling cascades, including the MAPK/ERK, PI3K/Akt/mTOR, and Wnt/beta-catenin pathways (Source: PubMed, PMID: 30214061). In drug discovery and clinical oncology, this process is used as a phenotypic endpoint to evaluate the efficacy of systemic therapies. Current pharmacological interventions typically utilize multi-kinase inhibitors, such as Sorafenib or Lenvatinib, which target the underlying proteins and growth factor receptors that stimulate this proliferation (Source: NIH, National Cancer Institute). Monitoring the rate of proliferation in patients often involves the use of serum biomarkers like Alpha-fetoprotein (AFP) to track disease progression and response to treatment (Source: StatPearls, NBK559033). Because it is a multi-factorial process involving genomic instability and metabolic reprogramming, it remains a primary challenge in the development of curative liver cancer therapies.

Other names

HCC proliferationLiver cancer cell growthHepatoma cell proliferationMalignant hepatocyte proliferation

Inhibition of upstream signaling pathways such as VEGFR, PDGFR, and Raf/MEK/ERK cascades to arrest the cell cycle and induce apoptosis in malignant hepatocytes.